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Background: In developing countries, many cases with rare neurological diseases remain undiagnosed due to
limited diagnostic experience. We encountered a case in China where two siblings both began to develop
idiopathic progressive cognitive decline starting from age six, and were suspected to have an undiagnosed
neurological disease.
Methods: Initial clinical assessments included review of medical history, comprehensive physical examination,
genetic testing for metabolic diseases, blood tests and brain imaging. We performed exome sequencing with
Agilent SureSelect exon capture and Illumina HiSeq2000 platform, followed by variant annotation and selection of
rare, shared mutations that fit a recessive model of inheritance. To assess functional impacts of candidate variants,
we performed extensive biochemical tests in blood and urine, and examined their possible roles by protein
structure modeling.
Results: Exome sequencing identified NAGLU as the most likely candidate gene with compound heterozygous
mutations (chr17:40695717C > T and chr17:40693129A > G in hg19 coordinate), which were documented to be
pathogenic. Sanger sequencing confirmed the recessive patterns of inheritance, leading to a genetic diagnosis of
Sanfilippo syndrome (mucopolysaccharidosis IIIB). Biochemical tests confirmed the complete loss of activity of
alpha-N-acetylglucosaminidase (encoded by NAGLU) in blood, as well as significantly elevated dermatan sulfate and
heparan sulfate in urine. Structure modeling revealed the mechanism on how the two variants affect protein
structural stability.
Conclusions: Successful diagnosis of a rare genetic disorder with an atypical phenotypic presentation confirmed
that such “genotype-first” approaches can particularly succeed in areas of the world with insufficient medical
genetics expertise and with cost-prohibitive in-depth phenotyping.Background
Next-generation sequencing (NGS) technologies have ad-
vanced many aspects of genomic sciences, and have accel-
erated the pace of discovery in biomedical research [1-3].
For example, NGS has been widely used in population
genetics studies [4,5], metagenomics [6,7], agrigenomics
[8,9], epigenetics [10] and gene expression studies [11,12].
In particular, human genome and exome sequencing can
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unless otherwise stated.traits that have proven to be intractable to conventional
gene-discovery strategies [13-16]. In addition, NGS em-
powers clinical diagnostics and other aspects of medical
practice, such as genetic diagnosis, disease prognosis,
therapeutic target identification, optimization of treatment
regimens, prenatal testing and personalized disease-risk
profiling.
Besides identifying new mutations in genes previously
implicated in known diseases, genome/exome sequencing
has also been used to characterize “idiopathic” or “mysteri-
ous” diseases, which present phenotypes that may be due
to genetic causes. The vast majority of such diseases are
indeed “known” diseases that cannot be easily diagnosed
by conventional candidate gene approaches, or require
complicated differential diagnosis. For example, a recent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pedigree of the family quartet under study. The carrier
status for the causal mutations in NAGLU are marked below each
subject in the family.
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ported a success rate of 25 percent to provide a genetic
diagnosis for 250 patients, who presented a range of phe-
notypes suggesting potential genetic causes and ~80%
were children with neurologic phenotypes [17]. An ex-
ome sequencing study on 100 patients with intellectual
disability found that 53 of them carried de novo mutations,
including 13 in known intellectual-disability genes, sug-
gesting that exome sequencing is an effective diagnostic
approach for diseases with extensive clinical heterogeneity
[18]. Additionally, several studies have reported the dis-
covery of completely novel diseases through genome/ex-
ome sequencing. One of the early examples was Ogden
syndrome, a previously unreported infantile lethal dis-
order, involving a mutation in NAA10 identified by us in
2011 using chromosome exon X capture and next-
generation sequencing [19]. A more recent example is a
novel genetic disease which we refer to as “Bookman syn-
drome”, a pediatric onset disease with neuromuscular and
cardiac involvement and with clinical features similar to
Glycogen Storage Disease Type IV. Although exome se-
quencing failed to identify the causes for the disease due
to technical reasons, we applied genome and transcrip-
tome sequencing and identified a disease-contributory
mutation in RBCK1 [20], which was further replicated by
another group [21]. Besides finding causal genes for gen-
etic diseases, genome/exome sequencing may also aid in
the treatment of rare diseases. One of the earliest high-
profile examples is the Pulitzer Prize-winning story of
Nicholas Volker, a young boy who at the age of 17 months
experienced perineal fistulae coupled with leakage of stool
via holes spanning from the intestine to the skin [22]. Ex-
ome sequencing on this boy resulted in a diagnosis of an
X-linked inhibitor of apoptosis deficiency. Based on this
finding, an allogeneic hematopoietic progenitor cell trans-
plant was performed on Volker. Altogether, these examples
demonstrated the power of genome/exome sequencing in
uncovering the genetic basis of idiopathic diseases and
finding treatments for them, even when only a very small
number of patient samples are available.
Among people with such diseases, those with idio-
pathic neuropathy present special challenges for genetic
diagnosis [23,24]. Due to the heterogeneous nature of
clinical presentation, the difficulty with characterizing phe-
notypes precisely, and the locus heterogeneity for the same
diseases, many patients with inherited neuropathy may not
obtain a genetic diagnosis by candidate gene testing. How-
ever, these patients may be more likely to receive a positive
diagnosis by exome sequencing interrogating all genes in a
somewhat unbiased manner, and multiple recent studies
have demonstrated successful examples [25,26]. Frequently,
after a candidate gene is identified, it is then found that an
atypical phenotype accounts for earlier failed candidate
gene approaches, so that genome/exome sequencing canindeed expand the clinical spectrum of previously reported
or novel mutations in known disease genes, especially for
patients with neuropathy [27]. Perhaps more importantly,
genome/exome sequencing can nominate important candi-
date genes or candidate diseases, which guides the selection
of functional assays to confirm the diagnosis of the disease.
In the current study, we describe a case study where
exome sequencing together with extensive biochemical
tests pinpointed the disease-contributory gene for an
idiopathic disease that failed to be diagnosed by conven-
tional means. This study involved a Chinese family quar-
tet (Figure 1) from Guangdong province, a relatively
more developed area in China, but even top hospitals in
these areas failed to give a diagnosis. It turned out that this
is a known disease with a known genetic basis, but with
an atypical phenotypic presentation such that appropriate
biochemical tests were not performed until mutations
pointing to this syndrome were identified. This ‘genotype-
first’ approach has been discussed before, which suggests
the need for the development of large, highly integrated
networks of researchers, clinicians, and patient families,
with the promise of improved therapies for subsets of
patients [28,29]. Our study has strong implications for
other extremely rare neuropathies, especially in areas
where highly experienced medical geneticists may not
be readily available.
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Clinical description
The two probands in our study are siblings from a family
in Guangzhou, Guangdong Province in China. The healthy
parents are non-consanguineous, and had one affected
son and one affected daughter (Figure 1). No evidence of
any similar genetic disease was reported in family mem-
bers. The study to identify disease genes through exome se-
quencing was approved by Jinan University First Affiliated
Hospital Institutional Review Board (reference number:
2013–004). An informed consent for participation of study
and publication of genetic results as well as individual med-
ical details was obtained from each family member (or their
guardians) who participated in the study.
Individual II-1 is a 10 year old boy. He was born at term
with normal birth parameters and good APGAR scores
(9/10/10). The neonatal period was uneventful, and he
had normal motor development during early childhood:
he began to look up at 3 months, sit by himself at
5 months, stand up at 11 months, walk at 13 months, and
speak at 17 months. He attended a regular kindergarten,
without any signs of difference in intelligence, compared
to his peers. Starting at age 6, the parents observed ever
increasing behavioral disturbance for the boy, manifesting
in multiple aspects of life. For example, he can no longer
wear clothes by himself, cannot obey instruction from par-
ents/teachers, can no longer hold subjects tightly in hand,
which were all things that he could do before 6 years of
age. In addition, he no longer liked to play with others; in-
stead, he just preferred to stay by himself, and he some-
times fell down when he walked on the stairs, which had
rarely happened at age 5. The proband continued to de-
teriorate: at age 9, he could not say a single word and had
no action or response to any instruction given in clinical
exams. Additionally, rough facial features were noted with
a flat nasal bridge, a synophrys (unibrow), a long and
smooth philtrum, thick lips and an enlarged mouth. He
also had rib edge eversion, and it was also discovered that
he was profoundly deaf and had completely lost the abil-
ity to speak. He also had loss of bladder control. The diag-
nosis of severe intellectual disability was made, based on
Wechsler Intelligence Scale examination. Brain MRI dem-
onstrated cortical atrophy with enlargement of the sub-
arachnoid spaces and ventricular dilatation (Figure 2).
Brainstem evoked potentials showed moderate abnormal-
ities. Electroencephalography (EEG) showed abnormal
sleep EEG.
Individual II-2 is a 9 years old girl. She was born at term,
also with normal birth parameters. She began to stand at
11 months, walk with aid at 13 months, and speak at
17 months. At age 5, she was just like other children of
similar age, with the ability to dress and sing, and count
by herself. Starting at 6 years of age, she began to show re-
gression of developmental patterns: she could not dress byherself anymore, and could not express even a single sen-
tence or count numbers. Clinical examination revealed a
coarse face with low anterior and posterior hairlines,
prominent frontal bossing, thick eyebrows, synophrys
(unibrow), hypertelorism, and thick lips. Growth parame-
ters were normal. Her clinical course was also severe, with
progressive neurodegeneration, behavioral problems (in-
cluding hyperactivity, impulsivity, obstinacy, anxious be-
haviors and autistic-like behaviors), and hearing loss. The
diagnosis of severe intellectual disability was made, based
on Wechsler Intelligence Scale examination. Measuring ac-
tivities of daily living showed extreme disability. Brain MRI
demonstrated cortical atrophy with enlargement of the
subarachnoid spaces and ventricular dilatation (Figure 2).
Brainstem evoked potentials showed moderate abnormal-
ities. EEG recording showed abnormal sleep EEG, just like
her brother’s manifestation.
Exome sequencing
We elected to perform exome sequencing on the pro-
bands, and to use parental samples for Sanger validation.
Genomic DNA was extracted from peripheral blood for
all family members by Qiagen DNeasy Blood & Tissue
kit (Valencia, CA, USA). We obtained at least 5ug DNA
from each sample, and all DNA samples passed quality
control measures for exome sequencing.
Exome capture was carried out on 1 μg of genomic
DNA, using the Agilent SureSelectXT Human All Exon
50 Mb kit (Agilent Technologies, Santa Clara, CA,
USA), which targets 50 Mb of coding exonic sequences,
which were annotated by the GENCODE project, CCDS,
miRbaseV14 and Sanger, as well as 10 base pairs of
flanking sequence of each exonic region and non-coding
RNA. The captured and amplified library was then
loaded onto the Illumina Hiseq2000 sequencer. We gen-
erated 100 bp paired-end reads in the sequencing run,
according to the manufacturer’s protocols. Raw images
were processed by Illumina Pipeline v1.3.4 for base-
calling with default parameters. Illumina SCS and
CASAVA software were used for raw data processing
and FASTQ file generation. In total, we obtained ~70
million reads per sample.
Sequence alignment and variant calling
For bioinformatics analysis of the FASTQ data from ex-
ome sequencing, we used SeqMule (http://seqmule.usc.
edu), which is an automated pipeline to execute multiple
alignment algorithms and multiple variant calling soft-
ware tools. Briefly, sequencing data was evaluated with
FastQC (http://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc/). Short reads were aligned to reference
genome (hg19) by BWA-MEM (version 0.7.4) [30] algo-
rithm with default settings. Then we used three variant
calling software tools, including the GATK version 3.1
Figure 2 Brain MRI of the two prodbands (A: brother 10 years old; B: sister 9 years old): Axial T1-weighted images showed that the
hemisphere sulci and schizencephaly general broadened and deepened. Double lateral and the third ventricle, cisterns were significantly
dilated. The gray matter and white matter of the two hemisphere decreased. All of the above changes indicated ventricular dilatation and cortical
atrophy in the two probands.
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0.9.14 [33] with default settings for exome sequencing.
We selected the consensus variants using the “two of
three algorithms” protocol, which specifies that variants
that were detected by at least two algorithms will be
present in the final consensus calling set.Variant annotation and prioritization
We used the ANNOVAR software [34] for functional
annotation of variants and the Tute web application
(tutegenomics.com) for identifying candidate variants
and genes for the clinical phenotype. We used a “single-
case analysis” pipeline to identify a list of candidate
genes with the following criteria: (1) identify variants
causing splicing or protein coding changes, including
stop loss and stop gain variants; (2) remove variants
with minor allele frequency (MAF) greater than 1% in
the PopFreqMax database from ANNOVAR package
[34], which include maximum allele frequency from the
1000 Genomes Project April 2012 release (five ethnicity
groups), the NHLBI-6500 Exomes (two ethnicity groups),
and the Complete Genomics 46 genomes (CG46) data-
base; (3) imposed a recessive mode of inheritance, with at
least two deleterious mutations found in each candidate
genes in the proband, and with the mutations shared by
both probands; (4) The resulting variants and genes were
sorted based on relevance to user-supplied phenotypes, as
well as annotations from clinical databases such as ClinVar
(version 20140303) and HGMD (version 2014_2) [35].Validation by Sanger sequencing
Selected putative variants were examined among all family
members using Sanger sequencing. Given the chromo-
somal position of variants, we designed PCR primers to
amplify fragments harboring individual variants by Pri-
mer3 [36]. The PCR primers were designed to encompass
the candidate position, ensuring that common SNPs are
not covered by the primers. The ABI 3730 XL sequencer
was used for sequencing, and the resulting *.AB1 files were
loaded into the ABI Sequence Scanner Software v1.0 for
further analysis and genotype calling. All sequence traces
were manually reviewed to ensure the reliability of the
genotype calls.
The primers used for chr17 :40695717(C > T) muta-
tion are CCCGCCTCTTCCCCAACTC (forward) and
GGACGCCTCCAGCCCTCAA (reverse). The primers
used for chr17 :40693129 (A > G) mutation are AAACC
AGGAGCTGTAGAGAAGT (forward) and CTGCCTA
CCCCTACTGACATCT (reverse).
Structure modeling
We searched the Protein Data Bank (PDB) [37] for struc-
ture models of NAGLU. Although the structure for hu-
man NAGLU was not available, a previous study solved
the crystal structure, catalytic mechanism, and inhibition
of CpGH89 from Clostridium perfringens, a close bacterial
homolog of NAGLU [38]. We downloaded the structure
from X-ray diffraction with a resolution of 2.36 Å with
binding of the ligand 2-Acetamindo-1,2-Dideoxynojirmy-
cin (PDB identifier: 2VC9). We built a structure model for
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quence identity. The template structure 2VC9 binds to
2-ACETAMIDO-1,2-DIDEOXYNOJIRMYCIN (PDB iden-
tifier: NOK). The position of NOK is decided by superposi-
tioning our model to the template structure 2VC9 (shown
in ball and stick). The 3D representation of the structure
was generated by PYMOL (http://www.pymol.org/).
Biochemical test in blood/urine
Enzyme activity was measured on peripheral blood leu-
kocytes using fluorogenic substrate obtained from Mos-
cerdam Substrates (Rotterdam, Netherlands); peripheral
blood leukocytes was collected and sonicated to protein
homogenates. Protein homogenates were incubated with
Moscerdam substrate. The parameters for enzyme activ-
ity was obtained by measuring the fluorescence intensity
and comparing with standard fluorescence intensity and
concentration. The assays were performed according to
the protocol at Department of Endocrinology and Metab-
olism, GuangzhouWomen and Children’s Medical Center
[40-44]. Urinary GAG was measured using dimethyl-
methylene blue/Tris by spectrophotometry and corrected
for urinary creatinine (Cr) content [45,46]. The ratio of
GAG/Cr (mg/mmol) was compared to age-matched nor-
mal controls (6 m-12 m, < 23.3; 12 m-36 m, <17.3; 3-5
years, <13.2; >5 years, < 9.7).
Results
Assessment of clinical information
The two probands were brother and sister one year apart
in age, and both of them had perfectly normal develop-
ment patterns in the first five years of age. Starting from
age six, the probands suddenly began to develop pro-
gressive speech and cognitive decline with behavioral
difficulties, motor function decline and hearing loss: they
gradually lost the ability to talk, count, or walk. Rough
facial features began to develop including synophrys
(unibrow), thick lips and enlarged mouth. Brain MRI
demonstrated cortical atrophy with enlargement of the
subarachnoid spaces and ventricular dilatation (Figure 2).
An extended list of clinical features is given in Materials
and Methods. In the course of the clinical workup, mul-
tiple attempts for genetic diagnosis were made, including
tests of chromosomal abnormalities and sequencing on a
panel for metabolic diseases. Multiple types of blood
screening tests and physical examinations were performed
on the pedigree, especially the probands, to exclude the
common inherited metabolic diseases and nervous system
abnormalities. Additional factors were considered to ex-
clude the possibility of food poisoning, environmental tox-
ification and other non-genetic reasons. However, none of
these attempts showed positive results, and these two pro-
bands were eventually referred to as having “mental de-
terioration of unknown origin”.To research the causes of the diseases in this family,
we examined all available phenotype information on the
probands. Both parents are healthy and are non-
consanguineous. No evidence of other genetic disease
was reported in any additional family members. We sus-
pected that this is an extremely rare or novel genetic
disease, possibly following a recessive pattern of inherit-
ance. Exome sequencing appeared to be the next natural
choice to identify candidate mutations possibly contrib-
uting to this idiopathic disease.
Exome sequencing identifies a prioritized list of candidate
mutations
To identify genetic causes for the disease in the family,
we performed exome sequencing on the two probands
with Agilent exon capture arrays, followed by sequen-
cing on the Illumina HiSeq2000 platform. For each pro-
band, we obtained approximately 70 million paired-end
reads of 100 base pairs. The mapping rates for reads
from brother (II-1) and sister (II-2) were 98.4% and
98.8%, respectively, and the on-target rates (fraction of
reads mapped to designed exome regions) were 54.9%
and 58.4%, respectively. We achieved a coverage of
68.2X and 71.3X over designed capture regions, and
with 88.3% and 88.5% of target regions covered by ≥10
reads for brother and sister, respectively (82.0% and
82.8% and covered by ≥20 reads). Data analysis was per-
formed using the SeqMule pipeline (http://seqmule.usc.
edu), which is an automated pipeline for analysis of
high-throughput sequencing data. It integrates multiple
alignment algorithms and multiple variant calling soft-
ware tools and gives user the flexibility to choose their
preferred aligners and variant callers, and enables gener-
ation of consensus calls from multiple calling algorithms
to improve reliability. We selected the consensus vari-
ants using the “two of three algorithms” protocol from
GATK v3.1 [31], SAMtools v0.1.19 [32] and FreeBayes
v0.9.14 [33], based on our previous work showing im-
proved accuracy when using multiple calling algorithms
[47]. The overlap of the three calling algorithms were
presented in Figure 3, demonstrating substantial differ-
ences between the variant callers, even when the same
alignment files were used. In total, 37,183 (2,268 indels)
and 37,822 (2,312 indels) variants were identified from
brother and sister respectively. To further identify likely
causal genetic variants from exome data, we used the
Tute web server which incorporates phenotype informa-
tion, a variant scoring system and several clinical data-
bases to rank variants and genes. NAGLU stands out as
the most likely candidate gene for the disease under a
recessive model (by requiring two predicted deleterious
mutations in the same gene).
We identified two compound heterozygous mutations
in NAGLU (N-acetylglucosaminidase, alpha), in both the
Figure 3 Venn diagrams showing the overlap of different variant calling algorithms on two exomes (II-1 and II-2). The three algorithms
are (1) GATK, (2) SAMtools and (3) FreeBayes. The numbers denote the number of called variants.
Table 1 Bioinformatics predictions of deleteriousness on
the two non-synonymous variants in NAGLU
p.Y309C p.R565W
SIFT score 0 0
SIFT prediction Deleterious Deleterious
PolyPhen score 1 1
PolyPhen prediction Probably damaging Probably damaging
LRT score 0 0
LRT prediction Neutral Deleterious
Mutation Taster score 1 1
Mutation Taster prediction Disease causing Disease causing
automatic
Mutation Assessor score 3.55 3.46
Mutation Assessor prediction High Medium
FATHMM score −6.27 −5.82
FATHMM prediction Deleterious Deleterious
MetaSVM score 1.05 1.05
MetaSVM prediction Deleterious Deleterious
MetaLR score 0.99 0.98
MetaLR prediction Deleterious Deleterious
Tute score 0.92 0.92
Tute prediction Deleterious Deleterious
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chr17:40693129A > G, c.926A > G, p.Y309C). Neither
variant was reported in the 1000 Genomes Project, the
NHLBI-ESP6500 exome sequencing project or the
Complete Genomics 46 genomes database. The first SNP
was documented in dbSNP with identifier rs104894597.
We evaluated the bioinformatics predictions on deleteri-
ousness of non-synonymous variants from the dbNSFP
database [48], and found that all algorithms gave largely
consistent predictions that both are deleterious (Table 1),
except that LRT predicted p.Y309C as “neutral”. NAGLU
encodes a lysosomal enzyme that degrades heparan sulfate
by hydrolysis of terminal N-acetyl-D-glucosamine residues
in N-acetyl-alpha-D-glucosaminides, which is the fifth step
of degradation of glycosaminoglycans (mucopolysaccha-
rides). Defects in this gene are the cause of mucopolysac-
charidosis type IIIB (MPS-IIIB), also known as Sanfilippo
syndrome B [49]. This disease is characterized by the lyso-
somal accumulation and urinary excretion of heparan sul-
fate. The clinical severity of MPS-IIIB is highly variable,
ranging from mild to severe, even in the same family, but
typically includes progressive neurodegeneration, behav-
ioral problems, mild skeletal changes, and shortened life
span [50-52]. To date, over 119 unique disease contribu-
tory mutations underlying MPS IIIB have been identified
in NAGLU in the Human Gene Mutation Database
(HGMD) [53]. Both mutations in the probands were
documented in HGMD as previously reported disease-
contributory mutations [54,55]. Only one mutation (p.
R565W) was documented in the ClinVar database (iden-
tifier: RCV000001633) as a “pathogenic” mutation.
Sanger validation of the candidate variants
To validate the presence of the mutations and to iden-
tify whether they are recessively inherited, we per-
formed Sanger sequencing on all the family members(Figure 4A,B). We found that the father and mother car-
ried the p.Y309C and p.R565W and mutations, respect-
ively, while the two probands inherited both variants
from their parents, resulting in compound heterozygous
mutations in NAGLU. Therefore, Sanger validation con-
firmed that these two mutations are inherited from dif-
ferent parents, which fits the known inheritance mode
of the Sanfilippo syndrome.
Figure 4 Sanger validation and structural modeling of the two compound heterozygous candidate variants in NAGLU in the family
quartet. (A) Validation of the chr17 :40695717(C > T) mutation by Sanger sequencing in the family. (B) Validation of the chr17 :40693129 (A > G)
mutation by Sanger sequencing in the family. (C) Structural location of mutation R565W and Y309C in NAGLU. We have built a structure model
based on a close homolog structure (PDB identifier: 2VC9) of CpGH89 from Clostridium perfringens. The template structure 2VC9 binds to
2-ACETAMIDO-1,2-DIDEOXYNOJIRMYCIN (PDB identifier: NOK).
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biochemical test
The analysis of candidate genes guided us to perform
functional studies to evaluate whether MPS-IIIB or other
types of MPS could explain the observed disease pheno-
types in the family. We tested eight MPS related enzymes,
including alpha-L-iduronidase, iduronate-2-sulfatase, hep-
aran sulfate sulfatase, alpha N-acetylglucosaminidase,
galactosamine 6-Sulfatase, β-galactosidase, arylsulfatase, β-
glucuronidase, which are responsible for different subtypes
of MPS (Table 2). The biochemical tests showed that
alpha-N-acetylglucosaminidase, which is encoded by
NAGLU, is completely inactive in both probands. Add-
itionally, the level of alpha-L-iduronidase was slightly
lower than reference value in one proband, but this could
be due to variations in measurement. The biochemistry re-
sults were consistent with the bioinformatics analysis, and
demonstrated that the two compound heterozygous muta-
tions are indeed loss-of-function mutations.
To further validate the consequences of the lack of en-
zyme activity for alpha-N-acetylglucosaminidase, we per-
formed urinary tests to measure the levels of metabolites
for the enzyme (Table 3). The level of urinary glucosami-
noglycan was extremely high in both probands, as opposedto an expected value of zero. Additionally, the substrates of
the NAGLU enzyme, including dermatan sulfate and hepa-
ran sulfate, are both positive in urine, further suggesting
that loss of function mutations in NAGLU leads to abnor-
mal accumulation of sulfate in urine, which may explain
the observed neuropathy.
Functional impacts of the candidate variants by structural
modeling
To further understand the functional impacts of the two
variants, we attempted to examine structure models for
NAGLU. A previous study solved the crystal structure,
catalytic mechanism, and inhibition of CpGH89 from
Clostridium perfringens, a close bacterial homolog of
NAGLU [38]. The structure was generated by X-ray dif-
fraction with a resolution of 2.36 Å. We built a structure
model for human NAGLU based on this template (PDB
identifier: 2VC9) using I-TASSER [39], given the high se-
quence identity. The complete structure contains four do-
mains (Figure 4C), including a N-terminal domain which
is a putative family 32 carbohydrate-binding module
(CBM) with the typical β-sandwich fold, a catalytic region
comprises a small α/β domain, an elaborated (α/β)8 barrel,
and an all α-helical domain that packs against the first
Table 2 Results of biochemical tests on the activity of MPS-related enzymes
Disease subtype Enzyme Gene Value (sister) Value (brother) Reference value Result Unit*
MPSI alpha-L-iduronidase IDUA 26.5 25.1 25.4-118.5 Borderline abnormal nmol/mg/h
MPSII iduronate-2-sulfatase IDS 31.4 32.2 30-120 normal nmol/mg/4 h
MPSIIIA heparan sulfate sulfatase SGSH 5.3 6.3 4.1-12 normal nmol/mg/17 h
MPSIIIB Alpha-N-acetyl-
glucosaminidase
NAGLU 0.0 0.0 5-22 abnormal nmol/mg/17 h
MPSIVA galactosamine
6- sulfate Sulfatase
GAS 72.2 68.1 40-170 normal nmol/mg/17 h
MPSIVB β-galactosidase lacZ 89.2 88.5 50.3-140.7 normal nmol/mg/h
MPSVI arylsulfatase Ars 67.0 49.0 50.4-175.2 normal nmol/mg/h
MPSVII β-glucuronidase GUSB 94.0 98.0 38.1-202.5 normal nmol/mg/h
*concentrations of metabolites (nmol/mg) after hour of incubation.
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not directly within the active site (ligand-binding site) of
NAGLU. Mutation Y309C is in the middle of the elabo-
rated alpha/beta barrel (in blue) and R565W is located at
the alpha-helical domain (in red) that packs against the
binding site. Therefore, mutation Y309C may affect the
structural stability of the alpha/beta barrel that constitutes
the bottom of the active site. Mutation R565W may plays
an important role in structural packing of the alpha-
helical domain that contributes to the stability of the
complete structure.
Discussion
In this study, we present a case illustrating the power of
NGS in clinical diagnosis of a rare disease in two siblings
with somewhat atypical phenotypes, with a disease onset
at ~ six years of age. Although this turned out to be a
known disease with a known genetic cause, our experi-
ence in this study is nevertheless revealing in the context
of a study conducted in China, where traditionally expe-
rienced medical geneticists are lacking. We suspected
that had a more experienced medical geneticist reviewed
the patient, biochemical tests on different types of MPS
could have been ordered, and a diagnosis of MPS-IIIB
may have been made without exome sequencing. How-
ever, in practice, numerous other tests were ordered and
all turned out to be negative, to a point where the family
was reluctant to pay for any additional tests. After exomeTable 3 Results from urinary test of glycosaminoglycan relate
Urinary test Value (sister) V
Urinary glycosaminoglycan (GAG) 528.1 4
Urinary glycosaminoglycan/Creatinine (GAG/Cr) 36.7 3
Dermatan sulfate + +
Heparan sulfate + +
Keratan - -
Chondroitin sulfate - -sequencing, the mutation pointed us to a phenotype re-
lated to MPS, and therefore we performed biochemical
tests in blood and urine to confirm this diagnosis. There-
fore, exome sequencing in this particular context provided
guidance for us to reach a final diagnosis, and this also il-
lustrates the importance of supporting bioinformatics pre-
dictions with functional evidence.
Sanfilippo syndrome B (or MPS-IIIB) is an extremely
rare disorder and the prevalence in China is unreported
and unknown. Due to the rare nature of the disease, the
incidence rate could vary significantly among different
parts of the world. Using multiple ascertainment sources,
one study obtained an incidence rate for Sanfilippo syn-
drome (form A + B +C) in western Australia for the
period 1969 to 1996 of approximately 1 in 58,000 live
births [56]. Since there were 5 people with type B in the
total of 11 cases, this suggested an incidence of MPS-IIIB
of approximately 1 in 127,600 live births. In different stud-
ies, an incidence of 1:24,000 was reported for all subtypes
of MPS III [52]. A more recent study on the Australian
population estimated an incidence rate of 1 in 200,000
[57]. Northern Ireland tends to have much lower incidence
of MPS, and a report showed the rate of 1 in 280,000 for
all subtypes of MPS III [58]. In the Netherland, the com-
bined birth prevalence for all subtypes of MPS-III is 1.89
per 100,000 live births [59].
While we emphasize that the development of tech-
nologies has now enabled rapid and relatively cost-d parameters
alue (brother) Reference value Result Unit
13.8 0 abnormal mg/L
9.7 <8.4 abnormal mg/mmol
- abnormal
- abnormal
- normal
- normal
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world, the major bottleneck is still the identification of
disease-contributory variants, which is heavily dependent
on the bioinformatics analysis of raw data and functional
interpretation of genetic variants. We used the SeqMule
pipeline for variant calling, to take ‘2 out of 3’ consensus
calls from three variant calling algorithms, in a way similar
to what the 1000 Genomes Project has been implementing
in their variant calling procedure. We also used ANNO-
VAR and the Tute web server for variant analysis focusing
on missense, nonsense and splice variants. For the two mis-
sense variants in NAGLU, we used multiple prediction al-
gorithms, including six from dbNSFP [48] (SIFT, PolyPhen,
LRT, Mutation Taster, Mutation Assessor, FATHMM), two
meta-scores built by us (MetaSVM, MetaLR), and the Tute
score (tutegenomics.com), and found that these algorithms
gave consistent predictions. However, the main reason we
focused on NAGLU is that it is reported in clinical data-
bases (ClinVar and HGMD) as containing mutations linked
to disease. This fact underscores the importance of curated
mutation databases in helping identify disease causal muta-
tions from newly sequenced genomes or exomes.
Conclusions
In conclusion, we have presented an example in China
where exome sequencing preceded and guided the selec-
tion of functional validations, to lead to a diagnosis of a
known disease with a somewhat atypical presentation.
With the ever decreasing cost of NGS and the rapid
adoption of NGS in clinical settings, we expect that gen-
ome/exome sequencing will be increasingly useful in the
diagnosis of rare genetic disorders with atypical pheno-
typic presentations, including in areas of the world
where experienced medical geneticists are scarce.Competing interests
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